Abeona Therapeutics, Inc. to Present on CRISPR/CAS9

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Abeona Therapeutics, Inc. to Present on CRISPR/CAS9 Technology Platform Progress at CRISPR Precision Gene Editing Congress

NEW YORK, NY and CLEVELAND, OH --(Marketwired - February 24, 2016) -  Abeona Therapeutics, Inc. ( NASDAQ : ABEO ), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced being featured in both a Poster and Abstract Presentation at the 2 nd Annual CRISPR Precision Gene Editing Congress in Boston, MA. The Poster and Abstract session will focus on CRISPR/Cas9 as a Promising Gene Editing Tool for Fanconi anemia and other rare blood disorders.

CRISPR/CAS9:

Introduction: Fanconi anemia (FA) is a rare inherited disease manifested by bone marrow failure and increased risk of malignancy. The c.456 + 4A> T (IVS4 + 4A> T) point mutation in FA complementation group C (FA-C) gene results in a cryptic splice site and causes aberrant splicing and in-frame deletion of FANCC exon 4. Gene editing is highly desirable alternative to allogeneic hematopoietic cell transplantation (HCT) for FA. In the present study, we have generated a CRISPR/Cas9 system for FANCC locus and demonstrated its usefulness in repairing the FANCC c.456+4A> T mutation.

Methods and Results: To test the ability of our custom-designed CRISPR/Cas9 reagents to mediate FANCC gene HDR, a transformed skin fibroblast culture was derived from an FA-C patient homozygous for the c.456+4 A> T mutation. The cells were treated with a donor plasmid and either the CRISPR/Cas9 nuclease or nickase. To determine whether genome editing by CRISPR/Cas9 resulted in restoration of exon 4 expression, HDR-specific PCR was performed using an allele specific RT-PCR. Interestingly, CRISPR/Cas9 nuclease and nickase clones each identified correction of c.456+4A> T compared to untreated and WT controls. Furthermore, to evaluate functional capability of our gene editing method, H2AX staining clearly demonstrated inability of untreated FA-C cells to phosphorylate γ-H2AX, however, the clones that were corrected by the nickase or the nuclease showed clear evidence to phosphorylate γ-H2AX. These findings confirm correction of the c.456+4A> T mutation at DNA, RNA and protein level.

An important safety concern of gene editing based correction strategy is potential for off target (OT) effects. To assess this important safety issue, a surveyor assay and an integration deficient lenti virus (IDLV) reporter gene trapping assay was performed and no OT activity for the nuclease or nickase was observed. Moreover, to identify the sites of integration of the IDLV, the samples were tested using LAM PCR and nonrestrictive (nr) LAM PCR, these results documented only on target events. In total, the data suggests highly specific CRISPR/Cas9 reagents.

Conclusions : To summarize, this data show that CRISPR/Cas9 mediated direct c.456 + 4A> T mutation repair resulted in normalization of the FANCC gene. This study also demonstrates that nickase was more efficient and reliable compared to nuclease. Furthermore, the gene editing model system established here provides support for a favorable safety profile using these synthetic molecules for correction of FA and other genetic disease in human cells.

About Abeona: Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are AB0-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). We are also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, management plans for the Company, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Company and Media Contacts: Andre'a Lucca Vice President of Communications & Operations Abeona Therapeutics, Inc. +1 (212)-786-6208 alucca@abeonatherapeutics.com Magdalena Tyrpien Director of Investor Relations Abeona Therapeutics, Inc. +1 (212)-786-6209 mtyrpien@abeonatherapeutics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stardock Fences 7 Targets Messy Windows Desktops Everywhere

Updated Category News Views 112

A cluttered Windows desktop is a tiny tax on attention, and Stardock has spent three decades selling people a way around it. Fences 7, released November 18, 2026, is the latest swing: a Windows 11-focused update that combines cosmetic polish with a genuinely practical privacy feature. This is not grand enterprise software, and nobody should pretend a $10 desktop utility...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 173

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 53

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
Fox Hill Steel Marks a Long Public-Building Road Ahead

Updated Category News Views 54

A signed steel beam is a fine civic moment, but it is not the finish line. Burlington’s new Fox Hill Elementary School has reached its topping-off milestone, with the structural steel now in place for a 91,000-square-foot, two-story facility intended to serve roughly 325 kindergarten-through-fifth-grade students. That is tangible progress, the sort nobody can fake with...

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 112

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 110

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Commodity Rout Tests a Market Already Short on Nerve

Updated Category News Views 24

Some weeks the tape merely wobbles; this one started throwing furniture. By midday Wednesday, traders were staring at sharp declines in gold, silver, crude and copper while the major equity benchmarks remained underwater for the week. That is an unpleasant combination. When growth-sensitive commodities and the usual hard-asset hiding places are all getting sold,...

Continue Reading
Pressure Injury Care Needs More Than Awareness Alone

Updated Category News Views 52

Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 172

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 198

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading

Top 5 Most Recently Viewed Articles

Petrus Resources Announces Exciting Monthly Dividend Update

Updated Category News Views 239

Petrus Resources Monthly Dividend Declaration Petrus Resources Ltd. (TSX: PRQ) is excited to share that its Board of Directors has declared a new monthly dividend. This dividend is set at $0.01 per share and is designated for the shareholders of record. The scheduled payment date is set for December 30, and this announcement comes with important information for...

Continue Reading
Important Update for Sprinklr Investors: Know Your Rights

Updated Category News Views 100

Key Update for Sprinklr Investors Investors who have experienced losses exceeding $100,000 in Sprinklr, Inc. should take a moment to examine their rights as shareholders. Faruqi & Faruqi, LLP, a well-regarded national securities law firm, is currently investigating possible claims against Sprinklr, which is listed on the NYSE under the ticker CXM. The firm is available to...

Continue Reading
Collaborative Innovations in Multi-Omics Data Management

Updated Category News Views 167

DNAnexus and Panomics Unite for Biopharma Excellence In the ever-evolving landscape of biopharma, data plays a pivotal role in shaping advancements and innovations. DNAnexus, a leader in precision health data management, and Panomics, renowned for AI-powered omics data discovery, have announced a collaborative initiative aimed at revolutionizing how biopharma...

Continue Reading
WisdomTree Investors May Have Claims to Explore: Pomerantz Insights

Updated Category News Views 41

Pomerantz Investigates Potential Investor Claims Pomerantz LLP is currently investigating claims on behalf of investors of WisdomTree, Inc. (NYSE: WT). This investigation suggests a focus on the possibility of securities fraud or other unlawful business practices that may involve the Company's officers or directors. Insights on WisdomTree's Recent Challenges Recent...

Continue Reading
Introducing ROADSAVER: A Breakthrough in Carotid Stenting

Updated Category News Views 365

Announcing the ROADSAVER Carotid Stent System Terumo Interventional Systems (TIS) is thrilled to announce the early commercial availability of the ROADSAVER™ Carotid Stent System. This FDA-approved device is specifically designed for patients with carotid artery stenosis, aiming to reduce complications that may arise after carotid endarterectomy. With the integration of...

Continue Reading